KR102280530B1 - 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체 - Google Patents

자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체 Download PDF

Info

Publication number
KR102280530B1
KR102280530B1 KR1020167015313A KR20167015313A KR102280530B1 KR 102280530 B1 KR102280530 B1 KR 102280530B1 KR 1020167015313 A KR1020167015313 A KR 1020167015313A KR 20167015313 A KR20167015313 A KR 20167015313A KR 102280530 B1 KR102280530 B1 KR 102280530B1
Authority
KR
South Korea
Prior art keywords
dopamine
asd
treatment
acid
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020167015313A
Other languages
English (en)
Korean (ko)
Other versions
KR20160088886A (ko
Inventor
아그네 오끌레르
폴 모세르
삐에르 쏘꼴로프
Original Assignee
피에르 파브르 메디카먼트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 피에르 파브르 메디카먼트 filed Critical 피에르 파브르 메디카먼트
Publication of KR20160088886A publication Critical patent/KR20160088886A/ko
Application granted granted Critical
Publication of KR102280530B1 publication Critical patent/KR102280530B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167015313A 2013-12-13 2014-12-12 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체 Expired - Fee Related KR102280530B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306726.4 2013-12-13
EP13306726 2013-12-13
PCT/EP2014/077635 WO2015086836A1 (en) 2013-12-13 2014-12-12 A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder

Publications (2)

Publication Number Publication Date
KR20160088886A KR20160088886A (ko) 2016-07-26
KR102280530B1 true KR102280530B1 (ko) 2021-07-21

Family

ID=49883003

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167015313A Expired - Fee Related KR102280530B1 (ko) 2013-12-13 2014-12-12 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체

Country Status (29)

Country Link
US (1) US10028948B2 (cg-RX-API-DMAC7.html)
EP (1) EP3079688B1 (cg-RX-API-DMAC7.html)
JP (1) JP6419826B2 (cg-RX-API-DMAC7.html)
KR (1) KR102280530B1 (cg-RX-API-DMAC7.html)
CN (1) CN105792824B (cg-RX-API-DMAC7.html)
AU (1) AU2014363428B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016012552A8 (cg-RX-API-DMAC7.html)
CA (1) CA2932791C (cg-RX-API-DMAC7.html)
CY (1) CY1119907T1 (cg-RX-API-DMAC7.html)
DK (1) DK3079688T3 (cg-RX-API-DMAC7.html)
ES (1) ES2657706T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180323T8 (cg-RX-API-DMAC7.html)
HU (1) HUE036035T2 (cg-RX-API-DMAC7.html)
IL (1) IL245996B (cg-RX-API-DMAC7.html)
LT (1) LT3079688T (cg-RX-API-DMAC7.html)
MA (1) MA39076A1 (cg-RX-API-DMAC7.html)
MX (1) MX372922B (cg-RX-API-DMAC7.html)
MY (1) MY172937A (cg-RX-API-DMAC7.html)
NO (1) NO3079688T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ720868A (cg-RX-API-DMAC7.html)
PL (1) PL3079688T3 (cg-RX-API-DMAC7.html)
PT (1) PT3079688T (cg-RX-API-DMAC7.html)
RS (1) RS56931B1 (cg-RX-API-DMAC7.html)
RU (2) RU2019104946A (cg-RX-API-DMAC7.html)
SA (1) SA516371298B1 (cg-RX-API-DMAC7.html)
SI (1) SI3079688T1 (cg-RX-API-DMAC7.html)
TN (1) TN2016000213A1 (cg-RX-API-DMAC7.html)
UA (1) UA117271C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015086836A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
CA3152645A1 (en) * 2019-09-11 2021-03-18 Oxford BioDynamics PLC Diagnostic chromosome marker
KR20220021157A (ko) 2020-08-13 2022-02-22 원광대학교산학협력단 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
DE4229880A1 (de) * 1992-09-04 1994-03-31 Knauf Siegfried Medikament bzw. Medikamentenzusammensetzung
CA2346689A1 (en) 1998-10-08 2000-04-20 Gregor James Macdonald Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
WO2006034187A2 (en) * 2004-09-20 2006-03-30 Mount Sinai School Of Medicine Use of memantine (namenda) to treat autism, compulsivity, and impulsivity
EP2263665A1 (en) * 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
FR2949465B1 (fr) * 2009-09-01 2011-08-12 Pf Medicament Derives chromones, leur procede de preparation et leurs applications therapeutiques
WO2011150380A1 (en) * 2010-05-28 2011-12-01 Xenoport, Inc. Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012157463A1 (en) * 2011-05-13 2012-11-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
FR2976179A1 (fr) * 2011-06-09 2012-12-14 Pf Medicament Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent

Also Published As

Publication number Publication date
ES2657706T3 (es) 2018-03-06
MA39076A1 (fr) 2017-05-31
AU2014363428A1 (en) 2016-06-23
JP6419826B2 (ja) 2018-11-07
BR112016012552A8 (pt) 2022-11-08
EP3079688A1 (en) 2016-10-19
HK1223563A1 (zh) 2017-08-04
PL3079688T3 (pl) 2018-05-30
RU2019104946A (ru) 2019-04-01
WO2015086836A1 (en) 2015-06-18
US10028948B2 (en) 2018-07-24
MX372922B (es) 2020-04-27
TN2016000213A1 (en) 2017-10-06
JP2016540000A (ja) 2016-12-22
IL245996A0 (en) 2016-07-31
RU2686110C1 (ru) 2019-04-24
HUE036035T2 (hu) 2018-06-28
RS56931B1 (sr) 2018-05-31
CN105792824B (zh) 2018-08-03
US20160303117A1 (en) 2016-10-20
IL245996B (en) 2018-11-29
LT3079688T (lt) 2018-02-12
SA516371298B1 (ar) 2018-06-07
NO3079688T3 (cg-RX-API-DMAC7.html) 2018-04-21
CN105792824A (zh) 2016-07-20
MX2016007612A (es) 2016-09-09
AU2014363428B2 (en) 2019-09-12
CA2932791C (en) 2021-11-09
HRP20180323T1 (hr) 2018-04-06
NZ720868A (en) 2022-04-29
CA2932791A1 (en) 2015-06-18
DK3079688T3 (da) 2018-01-29
SI3079688T1 (en) 2018-03-30
CY1119907T1 (el) 2018-06-27
PT3079688T (pt) 2018-02-28
UA117271C2 (uk) 2018-07-10
KR20160088886A (ko) 2016-07-26
MY172937A (en) 2019-12-16
HRP20180323T8 (hr) 2019-01-25
EP3079688B1 (en) 2017-11-22

Similar Documents

Publication Publication Date Title
Ross et al. Huntington disease
AU2014363428B2 (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder
Costa et al. Prospects for improving brain function in individuals with Down syndrome
Lee et al. Is oxytocin application for autism spectrum disorder evidence-based?
US20250235443A1 (en) Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
Cao et al. ErbB4 deletion in noradrenergic neurons in the locus coeruleus induces mania-like behavior via elevated catecholamines
JP7277458B2 (ja) 神経学的疾患を治療するための方法および組成物
US20230226019A1 (en) Mdma enantiomers
US20130164367A1 (en) Treatment of neurodegenerative disease with creb-binding protein
Kohlschütter et al. Epilepsy in neuronal ceroid lipofuscinoses
OA17906A (en) A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder.
US20240009180A1 (en) Medicine for alleviating neuropathic pain
HK1223563B (en) A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder
RU2812786C2 (ru) Применение ролуперидона для лечения негативных симптомов и заболеваний, повышения нейропластичности и содействия нейрозащите
Fonteneau et al. Tilted striatofugal balance and beneficial effects of facilitating mGlu4 receptor activity in the Fmr1-/-mouse model of Fragile X Syndrome
Konttinen et al. Microglial amyloid beta clearance is driven by PIEZO1 channels
TW202307217A (zh) 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法
CN121604971A (zh) 用于治疗与焦虑症相关的认知障碍的hip/pap蛋白或其衍生物
Alfei Palloni et al. Learning experience determines the fate of fear memories after post-training manipulations
Lopez et al. P. 4. a. 006 Cytokines in patients with fibromyalgia illness and anxious-depressive symptoms

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240717

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240717